News | May 16, 2025
Shelter Pharma launches three new products
Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India
Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India
Standalone profit from operations for the quarter were Rs. 162 crores
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
EBITDA before special items decreases to €4.08 billion (7.4%)
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Subscribe To Our Newsletter & Stay Updated
